Solvias helps innovative companies advance their path to commercialization with CMC analytical solutions powered by deep scientific expertise and a relentless focus on our customers’ success. With years of expertise in small molecules, biologics and cell and gene therapies, our talented subject matter experts have the know-how, creativity, and tenacity to solve even the most complex analytical challenges. Solvias offers comprehensive solutions from raw materials to drug products to final release testing as well as API development and manufacturing for small molecules. Customers have a single, trusted analytical partner for their entire development journey.

Our five global facilities are strategically placed in biopharmaceutical hubs. We are GMP, GLP and ISO certified and conduct over 100 successful customer audits every year. We take pride in putting science and quality at the heart of everything we do, helping our customers bring better and safer products to market faster.

For more information, visit solvias.com.

Solvias
480 Neponset Street, Bldg. 7
Canton, MA 02021
USA

Phone+1 (781) 821-5600
Websitewww.solvias.com
Emailinfo@solvias.com

LinkedIn logo

Products and Services

Extractables and Leachables Studies

Learn about our custom programs for multiple modalities that conform to the latest regulatory guidelines. With years of experience and extensive regulatory knowledge, we avoid common pitfalls and successfully manage highly complex studies using both simulated and custom design.

More Info

OINDP Testing

Solvias provides expert support across the entire OINDP development cycle on a wide range of products such as pressurized metered dose inhalers (pMDI), dry powder inhalers (DPI), nebulizers, nasal sprays, and soft mist inhalers (SMI). Our services span from analysis of early-stage candidates and device selection to commercial batch release.

More Info

Nitrosamine Testing

Solvias boasts a team of highly skilled experts with extensive knowledge in nitrosamine testing. We employ state-of-the-art technology, consistently delivering outstanding performance within the low parts-per-billion thresholds mandated by regulatory authorities.

More Info

↑ Back to Top